hs-CRP Biomarker Tracks Early Cardiovascular-Kidney-Metabolic Stages

Inflammation Jumps at Stage 1 of CKM Syndrome

High-sensitivity C-reactive protein (hs-CRP) nearly doubles at the earliest stage of cardiovascular-kidney-metabolic (CKM) syndrome, according to a cross-sectional study published in the European Journal of Preventive Cardiology. Researchers from the University of Eastern Finland and Rutgers Robert Wood Johnson Medical School evaluated data from 4,315 adults in the 2015 to 2018 National Health and Nutrition Examination Survey (NHANES). The participant group had an average age of 48 years, and half were women.

The American Heart Association (AHA) introduced CKM syndrome in 2023 to outline the clinical progression linking excess body fat, diabetes, kidney disease, and cardiovascular conditions. The framework spans stage 0 with no risk factors, stage 1 with excess or unhealthy body fat, stage 2 with chronic conditions like high blood pressure or type 2 diabetes, and stages 3 and 4 with early or established heart disease.

hs-CRP as a Biomarker Across Disease Stages

Blood levels of hs-CRP crossed the clinical risk threshold of 2 milligrams per liter during stage 1 and remained elevated through later stages. The shift between stage 0 and stage 1 represented the largest increase observed across the entire spectrum. After reaching this threshold, average values rose only modestly at stage 2 before leveling off across advanced stages.

The study authors noted that hs-CRP functions as an accessible marker of underlying inflammation rather than a direct target for treatment. Elevated readings reflect active systemic inflammation that emerges alongside excess body fat before overt cardiovascular or metabolic damage occurs.

Study Limitations and Research Gaps

The cross-sectional design of the survey means the data confirms a correlation rather than a cause-and-effect relationship. Because the researchers analyzed participants at a single point in time, the findings cannot determine whether elevated inflammation actively accelerates the progression of CKM syndrome.

Prospective cohort studies that monitor individuals over multiple years are required to track how inflammatory markers shift over time. Randomized clinical trials will also need to test whether early interventions aimed at reducing inflammation or body fat improve long-term outcomes.

Next Steps for Metabolic Health Discussions

An hs-CRP blood test provides an inexpensive tool to measure systemic inflammation during routine health evaluations. Lead author Douglas R. Corsi noted that detecting inflammation at the initial stage identifies the window where clinicians and patients have the most room to modify disease progression.

Senior author Andrew Agbaje emphasized that addressing excess body fat through dietary adjustments and lifestyle changes may help lower systemic inflammation. Patients interested in evaluating their baseline cardiovascular risk can talk to their clinician about ordering an hs-CRP test alongside standard metabolic panels.